Impressive Results Seen with Valeritas’ V-Go Wearable Insulin Delivery Device

Technology is once again changing lives for people with diabetes everywhere.

On Monday, Valeritas Holdings, Inc. announced that clinical data demonstrating use of its V-Go Wearable Insulin Delivery Device results in significant savings to the pharmacy budget, reductions in A1C and insulin requirements and overall improved treatment outcomes for patients with diabetes.

Results from two analyses will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting during a poster session on Tuesday, May 23 from 3:45 – 7:45 p.m. EDT in Boston.

“Both studies support that significant cost savings can be associated with improved clinical outcomes with the V-Go Wearable Insulin Delivery device for patients with diabetes,” said John Timberlake, President and Chief Executive Officer of Valeritas. “These clinical data highlight improvements found in real-world treatment outcomes for patients with diabetes, in addition to the financial benefit and value add provided by the V-Go Wearable Insulin Delivery device for both patients and the pharmacy budget.”

To read this morning’s full media announcement, click here.

This post was written by:

- who has written 2089 posts on mHealthWatch.


Contact the author

0 comments
Advert